argenx NV ADR (ARGX)vsInnoviva Inc (INVA)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
INVA
Innoviva Inc
$22.59
+3.06%
HEALTHCARE · Cap: $1.66B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 990% more annual revenue ($4.24B vs $388.52M). INVA leads profitability with a 32.8% profit margin vs 30.5%. INVA appears more attractively valued with a PEG of 0.33. INVA earns a higher WallStSmart Score of 81/100 (A-).
ARGX
Buy63
out of 100
Grade: C+
INVA
Exceptional Buy81
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+71.1%
Fair Value
$77.69
Current Price
$22.59
$55.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Growing faster than its price suggests
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 32.1%
Earnings expanding 5479.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : INVA
The strongest argument for INVA centers on PEG Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 32.8% and operating margin at 32.1%. Revenue growth of 20.4% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : INVA
The primary concerns for INVA are Market Cap.
Key Dynamics to Monitor
INVA carries more volatility with a beta of 0.49 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INVA scores higher overall (81/100 vs 63/100), backed by strong 32.8% margins and 20.4% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?